Epirubicin Inhibits Soluble CD25 Secretion by Treg Cells Isolated from Diffuse Large B-cell Lymphoma Patients

被引：2
作者：
Li, Lan-Fang [1 ]
Wang, Hua-Qing [1 ]
Liu, Xian-Ming [1 ]
Ren, Xiu-Bao [2 ]
机构：
[1] Tianjin Med Univ, Canc Hosp & Inst, Sino US Ctr Lymphoma & Leukemia, Dept Lymphoma, Tianjin, Peoples R China
[2] Tianjin Med Univ, Canc Hosp & Inst, Tianjin Key Lab Canc Prevent & Therapy, Dept Immunol, Tianjin, Peoples R China
来源：
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION | 2013年 / 14卷 / 03期
关键词：
Diffuse large B-cell lymphoma; CD4+CD25+regulatory T cells; epirubicin; soluble CD25; REGULATORY T-CELLS; PERIPHERAL-BLOOD; INCREASED POPULATIONS; INTERLEUKIN-2-RECEPTOR; CANCER;
D O I：
10.7314/APJCP.2013.14.3.1721
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objective: To investigate the effect of epirubicin on soluble CD25 (sCD25) secretion by CD4+CD25+ regulatory T (Treg) cells isolated from diffuse large B-cell lymphoma (DLBCL) patients. Methods: Treg cells were isolated from the peripheral blood mononuclear cells isolated from the newly diagnosed DBLCL patients. The concentration of sCD25 in the supernatant was determined with a commercial sCD25 (IL-2R) enzyme-linked immunosorbent assay (ELISA) kit. The fluorescence intensity of CD25 was detected by flow cytometry. Results: Cell survival rate was significantly decreased along with the increase of epirubicin concentration after treatment for 24 h. There was also a significant difference in the concentration of sCD25 between the epirubicin group and the control group (P<0.01). A positive correlation between the Treg cells survival rate and the concentration of sCD25 was detected (r=0.993, P<0.01). When equal numbers of CD4+CD25+ Treg cells of the epirubicin group and the control group were cultured for another 24 h without epirubicin the CD25 fluorescence intensity on the surface of Treg cells was obviously higher in the epirubicin group than that in the control group (P<0.01), while the sCD25 concentration in the supernatant in the epirubicin group was significantly lower than that in the control group (P<0.05). Conclusion: Epirubicin may improve the body's immune functions by inhibiting the sCD25 secretion by Treg cells in DLBCL patients.
引用
收藏
页码：1721 / 1724
页数：4
相关论文
共 12 条
[1]   Serum soluble interleukin 2 receptor in human cancer of adults and children: a review [J].
Bien, E. ;
Balcerska, A. .
BIOMARKERS, 2008, 13 (01) :1-26
[2]   Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells [J].
Chang, De-Kuan ;
Sui, Jianhua ;
Geng, Shusheng ;
Muvaffak, Asli ;
Bai, Mei ;
Fuhlbrigge, Robert C. ;
Lo, Agnes ;
Yammanuru, Anuradha ;
Hubbard, Luke ;
Sheehan, Jared ;
Campbell, James J. ;
Zhu, Quan ;
Kupper, Thomas S. ;
Marasco, Wayne A. .
MOLECULAR CANCER THERAPEUTICS, 2012, 11 (11) :2451-2461
[3]   Multicentre Hospital-based Case-control Study of Diffuse Large B-cell Lymphoma in Shanghai, China [J].
Fan, Rong ;
Zhang, Lu-Yao ;
Wang, Hong ;
Yang, Bo ;
Han, Tao ;
Zhao, Xiao-Li ;
Wang, Wei ;
Wang, Xiao-Qin ;
Lin, Guo-Wei .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (07) :3329-3334
[4]   Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells [J].
Felcht, M. ;
Heck, M. ;
Weiss, C. ;
Becker, J. C. ;
Dippel, E. ;
Mueller, C. S. L. ;
Nashan, D. ;
Sachse, M. M. ;
Nicolay, J. P. ;
Booken, N. ;
Goerdt, S. ;
Klemke, C. -D. .
BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (02) :348-358
[5]   Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index [J].
Goto, H ;
Tsurumi, H ;
Takemura, M ;
Ino-Shimomura, Y ;
Kasahara, S ;
Sawada, M ;
Yamada, T ;
Hara, T ;
Fukuno, K ;
Goto, N ;
Okuno, M ;
Takami, T ;
Seishima, M ;
Moriwaki, H .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2005, 131 (02) :73-79
[6]  
Ichihara F, 2003, CLIN CANCER RES, V9, P4404
[7]   T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies [J].
Lindqvist, Camilla A. ;
Christiansson, Lisa H. ;
Simonsson, Bengt ;
Enblad, Gunilla ;
Olsson-Stromberg, Ulla ;
Loskog, Angelica S. I. .
IMMUNOLOGY, 2010, 131 (03) :371-376
[8]   Identification of differentially expressed proteins in chemotherapy-sensitive and chemotherapy-resistant diffuse large B cell lymphoma by proteomic methods [J].
Liu, Yiping ;
Zeng, Liang ;
Zhang, Shusheng ;
Zeng, Shan ;
Huang, Jin ;
Tang, Youhong ;
Zhong, Meizuo .
MEDICAL ONCOLOGY, 2013, 30 (02)
[9]   Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma [J].
Liyanage, UK ;
Moore, TT ;
Joo, HG ;
Tanaka, Y ;
Herrmann, V ;
Doherty, G ;
Drebin, JA ;
Strasberg, SM ;
Eberlein, TJ ;
Goedegebuure, PS ;
Linehan, DC .
JOURNAL OF IMMUNOLOGY, 2002, 169 (05) :2756-2761
[10]   Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma [J].
Ormandy, LA ;
Hillemann, T ;
Wedemeyer, H ;
Manns, MP ;
Greten, TF ;
Korangy, F .
CANCER RESEARCH, 2005, 65 (06) :2457-2464
12